Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host adaptive immune receptors recognizing IBDV VP2 refer to the specialized B-cell receptors (BCRs) and T-cell receptors (TCRs) in avian species, particularly chickens, that specifically bind to the VP2 protein of the Infectious Bursal Disease Virus (IBDV) [1]. VP2 is the major structural protein of the IBDV capsid and serves as the primary target for neutralizing antibodies due to its highly immunogenic hypervariable region [2]. The interaction between VP2 and these adaptive receptors is the cornerstone of the host's protective immune response, leading to the production of antibodies and the activation of cell-mediated immunity [3]. In veterinary pharmacology, these receptors are the intended targets of vaccination strategies designed to prevent Gumboro disease, a highly contagious viral infection that causes significant economic losses in the poultry industry by destroying B-lymphocytes in the Bursa of Fabricius [4]. Effective engagement of these receptors by vaccine antigens is crucial for inducing long-lasting immunity and preventing the immunosuppression associated with IBDV infection [1]. However, the high mutation rate of the VP2 gene allows the virus to evolve and escape recognition by existing adaptive immune receptors, necessitating the continuous development of updated vaccines [2, 4]. [1] Müller, H., et al. (2003). Archives of Virology. [2] Letzel, T., et al. (2007). Journal of General Virology. [3] Rautenschlein, S., et al. (2002). Veterinary Immunology and Immunopathology. [4] Dey, S., et al. (2019). Poultry Science.
Antigen-specific activation of B-cell and T-cell receptors leading to signal transduction, clonal expansion, cytokine production, and the generation of neutralizing antibodies and memory cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host adaptive immune receptors recognizing Infectious Bursal Disease Virus VP2 (BCR/TCR (IBDV VP2)).